BioSpace News Archive

The executives, convicted under the RICO Act, were found guilty of bribing prescribers and defrauding insurers in order to increase sales of Subsys, a powerful opioid pain killer intended for use with cancer patients.

Researchers with the NYU School of Medicine and the University of Michigan identified a gene called ATDC that is necessary for the development of pancreatic cancer. They published their research in the journal Genes & Development.

The industry was shaken up when Tokyo-based Eisai and its collaboration partner, Biogen, announced they were abandoning huge swaths of their Alzheimer’s program related to aducanumab in late March.

Study shows how imipridone drugs ONC201 and ONC212 cause cancer cell death

Curbing the opioid crisis will continue to be a key focus for the FDA. Ned Sharpless talked about new packaging rules that are expected to help stem the concerns about too many opioids on the streets.

We interviewed Gaius Augustus, a PhD candidate at the University of Arizona, who is a participant in their Cancer Biology Graduate Interdisciplinary Program. He is also a bioinformatician, who regularly incorporates epidemiological data into his work.

The Society for Clinical Research Sites (SCRS) announced that Chris Hoyle, founder and executive director of Elite Research Network, has joined the organization’s Leadership Council.

When major depressive disorder (MDD) does not respond to at least two different types of antidepressant treatments in a moderate-to-severe depressive episode, it is reclassified as treatment-resistant depression or TRD. South San Francisco-based VistaGen Therapeutics’ AV-101 failed to meet its primary efficacy endpoints for TRD in a Phase II clinical trial.

In the study, tadalafil, the active ingredient in Cialis and Viagra, reversed the effects of heart failure, including the breathlessness associated with it.

Less than one year after securing a toehold in the United States, Korea-based Enzychem Lifesciences hit a major milestone with its pipeline as it eyes completion of its Phase II CRIOM (Chemoradiation Induced Oral Mucositis) study, which could lead to eventual commercialization of a treatment for the serious cancer treatment by-product.